Anzeige
Mehr »
Login
Donnerstag, 16.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Letzte Chance, bevor die Bohrer dieses "Monster"-Vorkommen bei einem 13-Millionen-Unternehmen ansteuern
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
546 Leser
Artikel bewerten:
(2)

VermiculusFT: B3 live with the first phase of its new cloud-native CSD system

Finanznachrichten News

STOCKHOLM, Jan. 16, 2025 /PRNewswire/ -- The Brazilian marketplace operator B3 has in December 2024, in partnership with Vermiculus Financial Technology, successfully deployed the initial phase of its new, elastically scalable, cloud-native CSD system.

With the new scalable CSD system, based on Vermiculus' microservice-based VeriSafeTM product, B3 will be able to handle expansive growth in the Brazilian market, preparing for e.g., a ten-fold increase in terms of capacity.

The new CSD platform provides B3 with a state-of-the-art CSD system, supporting extended opening hours as well as new functionalities, such as new reports for its market participants. The VeriSafe microservice architecture also allows for rapid time-to-market.

"Our new scalable CSD system has been successfully deployed, offering immediate benefits to our participants. By taking a gradual, soft-launch approach, we've ensured a seamless transition while maintaining stability and continuity for all users. This technology enabling us to scale effectively while introducing innovative functionalities to enhance operational efficiency for our participants," comments Viviane Basso, B3's Chief Operating Officer - Issuers, Depository and OTC.

The scalable Vermiculus CSD system, VeriSafeTM, is designed to meet the demands of large and complex depositories, capable of handling exceptional volume peaks while supporting a wide range of asset types and complex corporate actions. By using a unique microservice architecture, the system enables full efficiency whilst remaining reliable and robust.

"We have together designed a brilliant approach to a phased replacement of the current CSD, where we are combining a stable roll-over with providing market value from the very beginning. By initially running in parallel with the existing CSD, we ensure stability in the changeover. More importantly, we provide great value to the market, as we provide desired new functionality and market output to the participants from the very beginning," says Taraneh Derayati, CEO of Vermiculus.

Parallel with the deployment of phase 1, B3 and Vermiculus continue to work on second phase of the CSD project, where a wide range of different transaction types will be re-directed and processed directly by the VeriSafe system, making it the golden source of depository information. This iterative development will allow for continuous improvements, positioning the new CSD system as an adaptable and resilient solution in a rapidly changing market.

Taraneh Derayati, CEO of Vermiculus; Viviane Basso, B3's Chief Operating Officer - Issuers, Depository and OTC

About Vermiculus Financial Technology

Vermiculus Financial Technology AB provides cutting-edge trading, clearing, and CSD solutions to market participants around the world. Vermiculus' solutions are the first to bring state-of-the-art advances in dynamic microservice architecture together with vast experience in clearing house, exchange, and CSD business requirements.

The company started its operation in 2020 and is founded by industry experts with the incentive to revolutionize the technology of exchanges, clearing houses, and CSDs. With its headquarters in Stockholm, Sweden, Vermiculus consists of hand-picked teams, trained to deliver mission-critical solutions. With decades of accumulated knowledge and expertise, the team has previously completed 75+ projects for the world's largest exchanges, clearing houses, and CSDs.

For further information, please contact:
Amelie Hedenstierna - PR & Communications
Vermiculus Financial Technology
Tel +46-(0)73 622 24 54
amelie.hedenstierna@vermiculus.se

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/vermiculusft/r/b3-live-with-the-first-phase-of-its-new-cloud-native-csd-system,c4092267

The following files are available for download:

https://news.cision.com/vermiculusft/i/viviane-basso-b3,c3368561

Viviane Basso B3

https://news.cision.com/vermiculusft/i/taraneh-derayati--ceo-of-vermiculus,c3368568

Taraneh Derayati, CEO of Vermiculus

https://news.cision.com/vermiculusft/i/viviane-basso--b3-s-chief-operating-officer---issuers--depository-and-otc,c3368598

Viviane Basso, B3's Chief Operating Officer '" Issuers, Depository and OTC

Cision View original content:https://www.prnewswire.co.uk/news-releases/b3-live-with-the-first-phase-of-its-new-cloud-native-csd-system-302353172.html

© 2025 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.